NM (nemaline myopathy) is a rare genetic muscle disorder defined on the basis of muscle weakness and the presence of structural abnormalities in the muscle fibres, i.e. nemaline bodies. The related disorder cap myopathy is defined by cap-like structures located peripherally in the muscle fibres. Both disorders may be caused by mutations in the TPM2 gene encoding β-Tm (tropomyosin). Tm controls muscle contraction by inhibiting actin–myosin interaction in a calcium-sensitive manner. In the present study, we have investigated the pathogenetic mechanisms underlying five disease-causing mutations in Tm. We show that four of the mutations cause changes in affinity for actin, which may cause muscle weakness in these patients, whereas two show defective Ca2+ activation of contractility. We have also mapped the amino acids altered by the mutation to regions important for actin binding and note that two of the mutations cause altered protein conformation, which could account for impaired actin affinity.
Skip Nav Destination
Follow us on Twitter @Biochem_Journal
Article navigation
February 2012
-
Cover Image
Cover Image
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
Research Article|
January 27 2012
Abnormal actin binding of aberrant β-tropomyosins is a molecular cause of muscle weakness in TPM2-related nemaline and cap myopathy Available to Purchase
Minttu Marttila;
Minttu Marttila
*The Folkhälsan Institute of Genetics, Biomedicum Helsinki, Finland
†Department of Medical Genetics, Haartman Institute, University of Helsinki, Biomedicum Helsinki, Finland
Search for other works by this author on:
Elina Lemola;
Elina Lemola
*The Folkhälsan Institute of Genetics, Biomedicum Helsinki, Finland
†Department of Medical Genetics, Haartman Institute, University of Helsinki, Biomedicum Helsinki, Finland
Search for other works by this author on:
William Wallefeld;
William Wallefeld
‡Molecular Neurogenetics Laboratory, Centre for Medical Research, West Australian Institute for Medical Research, University of Western Australia, Queen Elizabeth II Medical Centre, Nedlands, WA, Australia
Search for other works by this author on:
Massimiliano Memo;
Massimiliano Memo
§National Heart and Lung Institute, Imperial College London, London SW3 6LY, U.K.
Search for other works by this author on:
Kati Donner;
Kati Donner
∥Department of Medicine, University of Helsinki, Helsinki, Finland
Search for other works by this author on:
Nigel G. Laing;
Nigel G. Laing
‡Molecular Neurogenetics Laboratory, Centre for Medical Research, West Australian Institute for Medical Research, University of Western Australia, Queen Elizabeth II Medical Centre, Nedlands, WA, Australia
Search for other works by this author on:
Steven Marston;
Steven Marston
§National Heart and Lung Institute, Imperial College London, London SW3 6LY, U.K.
Search for other works by this author on:
Mikaela Grönholm;
Mikaela Grönholm
¶Division of Biochemistry and Biotechnology, Department of Biosciences, University of Helsinki, Helsinki, Finland
Search for other works by this author on:
Carina Wallgren-Pettersson
Carina Wallgren-Pettersson
1
*The Folkhälsan Institute of Genetics, Biomedicum Helsinki, Finland
†Department of Medical Genetics, Haartman Institute, University of Helsinki, Biomedicum Helsinki, Finland
1To whom correspondence should be addressed (email [email protected]).
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
June 10 2011
Revision Received:
November 15 2011
Accepted:
November 16 2011
Accepted Manuscript online:
November 16 2011
Online ISSN: 1470-8728
Print ISSN: 0264-6021
© The Authors Journal compilation © 2012 Biochemical Society
2012
Biochem J (2012) 442 (1): 231–239.
Article history
Received:
June 10 2011
Revision Received:
November 15 2011
Accepted:
November 16 2011
Accepted Manuscript online:
November 16 2011
Citation
Minttu Marttila, Elina Lemola, William Wallefeld, Massimiliano Memo, Kati Donner, Nigel G. Laing, Steven Marston, Mikaela Grönholm, Carina Wallgren-Pettersson; Abnormal actin binding of aberrant β-tropomyosins is a molecular cause of muscle weakness in TPM2-related nemaline and cap myopathy. Biochem J 15 February 2012; 442 (1): 231–239. doi: https://doi.org/10.1042/BJ20111030
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Biochemical Society Member Sign in
Sign InSign in via your Institution
Sign in via your InstitutionGet Access To This Article
Follow us on Twitter @Biochem_Journal
Open Access for all
We offer compliant routes for all authors from 2025. With library support, there will be no author nor reader charges in 5 journals. Check here |
![]() View past webinars > |